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Abstract
Background: Long-acting injectable antiretroviral therapy (LA ART) has been shown to be non-inferior to daily oral
ART, with high patient satisfaction and preference to oral standard of care in research to date, and has recently
been approved for use in the United States and Europe. This study examined the perspectives of health care
providers participating in LA ART clinical trials on potential barriers and solutions to LA ART roll-out into real world
settings.
Methods: This analysis draws on two data sources: (1) open-ended questions embedded in a structured online
survey of 329 health care providers participating in the ATLAS-2 M trial across 13 countries; and (2) in-depth
interviews with 14 providers participating in FLAIR/ ATLAS/ATLAS-2 M trials in the United States and Spain. Both
assessments explored provider views and clinic dynamics related to the introduction of LA ART and were analyzed
using thematic content analysis. The Consolidated Framework for Implementation Research (CFIR) was drawn on as
the conceptual framework underpinning development of a model depicting study findings.
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Results: Barriers and proposed solutions to LA ART implementation were identified at the individual, clinic and health
system levels. Provider perceptions of patient level barriers included challenges with adhering to frequent injection
appointments and injection tolerability. Proposed solutions included patient education, having designated staff for
clinic visit retention, and clinic flexibility with appointment scheduling. The main provider concern was identifying
appropriate candidates for LA ART; proposed solutions focused on patient provider communication and decision
making. Clinic level barriers included the need for additional skilled individuals to administer injections, shifts in
workflow as demand increases and the logistics of cold-chain storage. Proposed solutions included staff hiring and
training, strategic planning around workflow and logistics, and the possibility of offering injections in other settings,
including the home. Health system level barriers included cost and approvals from national regulatory bodies. Potential
solutions included governments subsidizing treatment, ensuring cost is competitive with oral ART, and offering co-pay
assistance.
Conclusions: Results suggest the importance of multi-level support systems to optimize patient-provider communication
and treatment decision-making; clinic staffing, workflow, logistics protocols and infrastructure; and cost-related factors within
a given health system.
Keywords: HIV, ART, Long-acting injectable, Implementation, Health care providers, Clinical settings
Background
Antiretroviral therapy (ART) to treat human immuno-
deficiency virus (HIV) is highly effective when taken
regularly. Daily oral ART can help people living with
HIV (PLHIV) to achieve and maintain life-long viral
suppression, but requires consistent adherence over a
life time [1]. Several decades into the use of ART, there
is substantial evidence of sub-optimal adherence to oral
ART across settings and populations [2]. Barriers to
daily oral ART adherence include those imposed by
characteristics of pill regimens and their side effects,
health care systems and provider communication issues
[3–5]. Significant psychosocial and structural barriers in-
clude substance use and mental health [6–9], inequitable
gender norms and roles [7, 10], and stigma and discrim-
ination associated with HIV and marginalized popula-
tions disproportionately affected by the epidemic [11,
12]. A new delivery method, long-acting injectable (LA)
ART, offers an alternative to oral regimens which may
address some of these adherence challenges. Clinical tri-
als of a two-drug intramuscular (IM) long-acting regi-
men of Cabotegravir (CAB) and Rilpivirine (RPV) [13–
16] have demonstrated that LA ART is non-inferior to
daily oral ART, showing rates of viral suppression, treat-
ment failure, and drug resistance similar to daily oral
ART [17–19].
LA ART requires periodic injections, monthly or every
2 months, eliminating the need for taking daily pills.
This may provide a more convenient and, for some
PLHIV, a more private option. This new treatment mo-
dality may present the possibility of improved adherence
to therapy and thus has the potential to improve individ-
ual level outcomes including viral suppression, and as a
result, population level transmission dynamics [20]. Prior
research has documented acceptability of LA ART
among PLHIV [21–24] and satisfaction with LA ART
among clinical trial participants [25–28]. In a qualitative
study we conducted with patients and health care pro-
viders participating in the LATTE-2 phase 2 trial [25],
providers were generally supportive of LA ART as a
treatment option. However, they expressed clinic readi-
ness concerns including the requirement for patients to
attend more frequent clinic visits and the need for suffi-
cient trained health care staff to administer injections
[25]. These practical questions and concerns under-
scored the need for further research exploring provider
perceptions of the feasibility of implementing LA ART
and how potential challenges might be addressed. Given
that LA ART has recently been approved for use in set-
tings such as the United States and Europe [29, 30],
work to optimize implementation is timely and strategic.
We conducted formative research in the context of
clinical efficacy trials to assess potential barriers to LA
ART implementation and possible solutions. In this
qualitative study, we examine perspectives of health care
providers using LA ART in clinical trials to assess chal-
lenges and opportunities for future roll-out of LA ART
with the ultimate goal of optimizing implementation of
LA ART delivery in routine clinical care and, in turn,
improving the health outcomes of PLHIV.
Methods
Study design
We employed a multi-methods approach [31] combining
two sources of data collection and two methods of data
analysis for this qualitative study using a cross-sectional,
exploratory design. Our analysis draws on data from
both open-ended questions embedded in a structured
online survey conducted with 329 health care providers
from 13 countries participating in the phase 3 ATLAS-2
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M trial and 14 in-depth interviews (IDIs) with health
care providers in the United States and Spain participat-
ing in the ATLAS, ATLAS-2M and FLAIR phase 3 clin-
ical trials of LA ART [14–16]. ATLAS and ATLAS-2M
enrolled treatment-experienced participants while FLAI
R enrolled treatment-naïve participants whose virus had
been suppressed using coformulated abacavir/ lamivu-
dine/ dolutegravir for 20 weeks. All three trials required
participants to take oral CAB + RPV for 4 weeks prior to
LA ART to ensure tolerability. ATLAS and FLAIR trials
randomized participants to continue on oral ART or
switch to monthly injections. ATLAS-2M randomized
participants to receive injections monthly or every 2
months.
We developed a semi-structured, in-depth interview
guide (provided as Additional File 1) for health care pro-
viders in the United States and Spain participating in the
ATLAS, ATLAS-2M and FLAIR trials based on prior
formative research conducted with providers in the
phase 2b LATTE-2 study. The guide contained a series
of open-ended questions aimed at exploring provider,
clinic and health system issues related to LA ART. Four-
teen semi-structured IDIs were conducted with health
care providers using the guide to elicit their views on
and experiences with LA ART. For IDIs in the U.S.,
three urban clinical sites were included: Washington,
D.C., Omaha, Nebraska and San Francisco, California. In
Spain, eight sites participated in the study from six di-
verse geographic locations, including major urban re-
search hospitals as well as smaller and more rural
clinics. Two of the sites were in Madrid, two were in
Barcelona, and one site each were in Santiago de Com-
postela, La Coruña, Valencia, and Palma de Mallorca.
In parallel, we developed a structured online survey
(provided as Additional File 2) to assess the feasibility of
LA ART across a geographically diverse and larger
sample of health care providers participating in a clinical
trial of LA ART. The survey development was primarily
based on the key themes raised by providers in our prior
formative work with health care providers participating
in the LATTE-2 study. Additional insights were gleaned
from the literature, advisory boards, and pilot-testing
with investigators from the ATLAS-2M study. The sur-
vey was administered to providers in the ATLAS-2M
trial to further understand their views and clinic and
health system dynamics related to the introduction of
LA ART, including barriers to implementation and op-
portunities for roll-out. The survey included three open-
ended questions asking 1) what providers considered to
be the most significant barriers to successful implemen-
tation of LA ART, 2) how those barriers could be over-
come, and 3) what would be needed for their site to
implement LA ART once it is available. The survey was
first developed in English and then translated into 7 lan-
guages: French, German, Italian, Korean, Russian, Span-
ish, and Swedish.
Study participants and sample composition
Characteristics of interview participants and survey re-
spondents are shown in Table 1. Of the 14 providers
who participated in the IDIs, 6 were from the U.S. and 8
were from Spain. All individuals were involved in the
phase 3 trials, either as study investigators (physicians)
(n = 10) or study staff (e.g. study coordinators, nurses or
other project staff) (n = 4) and all had contact with pa-
tients receiving LA ART as part of these trials. Spain
and the U.S. and the specific clinics within these two
countries were chosen for the qualitative study based on
consideration of factors such as geographic diversity, the
large number of people enrolled in the trials in those
settings, and established on-the-ground partnerships.





n (%) n (%)
Region Europe 158 (61%) Spain 6 (43%)
North America 61 (24%) U.S. 8 (57%)
East Asia and the Pacific 16 (6%)
Africa 13 (5%)
Latin America 10 (4%)
Clinical role Physician 156 (60%) Physician 10 (72%)
Nurse/Study Nurse/PA 64 (25%) Nurse 2 (14%)
Research Staff 29 (11%) Administrator 2 (14%)
Pharmacist 9 (4%)
Prior LA ART trial involvement 1–2 clinical trials 134 (52%) ATLAS/ATLAS-2 M 8 (57%)
3 or more clinical trials 124 (48%) FLAIR 6 (43%)
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The online survey was sent to a total of 449 clinical
trial staff, 329 (73%) of whom initiated the survey. Of
those, 258 (78%) submitted responses to any of open-
ended questions regarding implementation barriers and
solutions. Providers participating in the survey who
responded to the open-ended questions came from five
geographic regions including: 61% from Europe (France,
Italy, Germany, Russia, Spain, Sweden), 24% from North
America (Canada, the United States), 6% from Asia and
the Pacific (Australia, South Korea), 5% from Africa
(South Africa), and 4% from Latin America (Argentina,
Mexico). More than half of providers, or 60%, were phy-
sicians, 25% were nurses or physician assistants, 11%
were research staff and 4% were pharmacists. Most of
these providers had participated in more than one trial
related to LA ART, with 52% having participated in one
or two trials and 48% participating in three or more LA
ART trials.
Data collection and management
For IDIs, providers were identified by study investigators
from the local trial sites. Written informed consent was
obtained from all providers prior to the interviews which
were conducted at the participating clinics in the U.S.
and Spain. Interviews were conducted in the local lan-
guage (English or Spanish) and lasted approximately 60
min. Interviews were audiotaped and transcribed verba-
tim in the language in which they were conducted. The
study team used unique identifiers to label forms and
audiotapes; no identifiers were included in transcriptions
of the interviews. Transcripts were imported into
Atlas.ti© [32] qualitative data analysis software for ana-
lysis. Interviews were completed between April and Sep-
tember 2018.
For the survey, study investigators received an email
from the trial sponsor (ViiV Healthcare) describing the
survey and requesting they identify eligible candidates
from their sites. Potential participants were sent an email
with information about the survey and the link to the
online survey. Participants provided consent to partici-
pate on the first screen of the survey which was adminis-
tered using Qualtrics© [33] software before any
questions appeared. Providers were given 2 weeks to
complete the survey and for those who did not respond,
they were sent a reminder email. The survey took ap-
proximately 20 min for providers to complete and was
conducted between February and May 2019.
Analysis
In-depth interviews
IDI transcripts were analyzed using an iterative thematic
content analysis approach [34]. A codebook was devel-
oped in English and used to inform the coding structure
from a priori codes based on the original interview guide
and study objectives. Additional domains emerging from
the data were evaluated by two independent coders and
the study investigators for relevance and accuracy. These
were then added to the codebook during the process of
refining the thematic coding structure. Transcripts were
coded for both a priori and emergent domains of inter-
est [35]. Throughout the coding process, saturation of
themes was monitored, ensuring that thematic redun-
dancy was established, and that little new information
related to the primary domains was emerging [36]. It
was expected there would be uniformity in clinician per-
spectives across sites in the two countries, and the
homogeneous nature of the population would require a
smaller sample [37]. With 10 of the 14 IDI participants
serving as study investigators at their sites, most inter-
view participants shared a specific role and thus had ex-
posure to similar aspects of the administration of LA
ART at their sites, resulting in a convergence of views in
the data and saturation being achieved in the sample.
Survey responses
Textual data from open-ended survey responses were
analyzed using a deductive content analysis approach.
All data were reviewed for content and entered into a
categorization matrix grouped by themes generated
through the use of hierarchical codes [38]. The hierarch-
ical coding frame was developed using the type of barrier
and additional granularity for sub-codes when needed
(e.g. injection frequency, scheduling). Validity of the
matrix was assessed to confirm that categories ad-
equately represented the concepts and the matrix cap-
tured what was intended [39]. Analytic summaries were
written per country and per region to synthesize output.
Responses were examined across countries and regions
to assess similarities and differences and global themes
were then extracted from across the summaries.
Comparisons were drawn between the two data
sources to determine for which domains the data from
the interviews and the survey converged. The level of
convergence was high among the interview participants,
even across the two country settings, and lower among
survey participants both across and within countries (e.g.
divergence in the data across providers from the same
country as well as from one country to the next). These
difference made it particularly compelling when we iden-
tified convergence between the survey data and the
interview data and directed our analysis to focus on
these key domains on which we found convergence be-
tween the two data sources. Themes extracted from IDIs
were mapped onto the matrix of themes from survey re-
sponses and supporting quotes from IDIs were added.
Based on thematic groupings from the code output and
summaries of each data source, results were organized
by patient, clinic, and systems level considerations.
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Given its emphasis on multi-level influences on imple-
mentation, we used the Consolidated Framework for Im-
plementation Research (CFIR) [40] to help organize our
findings. The CFIR provides a theoretical framing for
using formative research to inform implementation of
an innovation such as LA ART and includes the follow-
ing five domains: individual, inner setting, outer setting,
intervention and process. We drew on the CFIR to in-
form the development of a model situating findings
within the established and well-understood domains of
the individual, inner setting, and outer setting.
Results
Across interview and survey data, health care providers
identified potential barriers and possible solutions to
implementing LA ART at multiple levels including: the
individual level, thinking about their patients’ needs and
preferences and their own role and attitudes as providers
in this process; the clinic level, assessing clinic opera-
tions and structure; and the systems level, considering
national regulations and health care coverage in their
countries. Findings presented below include the key
themes around which the data converged from both data
sources and are organized by individual, clinic, and
health system level.
For each level, we present a synopsis of the most frequent
and salient responses from survey respondents and inter-
view participants. Illustrative quotes from IDIs provide fur-
ther nuance and description throughout the narrative and a
table follows which summarizes potential barriers and pro-
posed solutions from survey participants with direct quotes
from responses to the open-ended survey questions.
Individual level considerations
Provider perceptions of patient barriers and proposed
solutions
At the individual level, providers perspectives on patient
barriers focused on injection frequency and tolerability.
Providers had concerns about the frequency of the injec-
tion appointments including patient non-adherence and
the risk of resistance due to missed appointments,
scheduling challenges, and clinic access, specifically dis-
tance to clinics and the challenge of patients not being
able to return for a timely visit for each injection. Pro-
viders perceived injection tolerability to be another key
barrier for patients, both in terms of pain at the time of
the injection and injection site reactions following ad-
ministration of treatment. An IDI participant in the U.S.
highlighted concerns about both injection frequency and
tolerability for patients saying:
I think the biggest drawback is just, one, having to go
to your doctor’s office every month and then, two,
just the pain of an injection. It’s a lot more painful
than swallowing a pill. (U.S. study coordinator, IDI
participant)
Capturing the concern around clinic accessibility, an
interview participant in the U.S. discussed her experi-
ence in the trials with staff efforts needed to help pa-
tients adhere to appointments:
I think the challenge is to be able to get them to be
able to get to you. Some places are just not the easi-
est places to get to. I always think that my patients
do well in clinical trials because of the contact with
somebody that’s so constant. You don't show up, the
study nurse calls you and says “Hey, where are you?”
(U.S. physician and PI, IDI participant)
Across interviews and survey responses, patient educa-
tion came up as a proposed solution for both helping pa-
tients understand the importance of adhering to
injection appointments and in tolerating injection-
related pain. An in-depth interview participant in the
U.S. described the need for patient education as follows:
Have somebody able to educate [patients] as far as
what to expect. Most of our patients who have gotten
injectable medications, the first ones are pretty painful,
but after that it keeps getting less and pretty soon they
don't even really notice it anymore. I feel like having
somebody who knows what information to tell them,
kind of walking them through, telling them what to ex-
pect, during those first few injections, is important.
(U.S. nurse and study coordinator, IDI participant)
Another common proposed solutions to patient level
barriers was to ensure clinic flexibility with appointment
scheduling. One interview participant from the U.S. de-
scribed the way her team has worked around scheduling
challenges with trial participants at their site:
A lot of times, we’ll start study visits earlier in the morn-
ing. Sometimes we'll come in at 7:00 or 7:30 to start see-
ing some of those patients that are working. We've had a
couple of patients, “Hey, I'm going to Europe from this
date to this date.” So we've had to do a little bit of cre-
ative work in communicating with the team about mak-
ing it work with their injection schedules. (U.S. nurse &
study coordinator, IDI participant)
As shown in Table 2, additional solutions proposed by
survey respondents included patient incentives, peer
navigators, appropriate injection techniques to minimize
pain, alternative locations for injection administration,
and less frequent dosing (every 2 months versus
monthly).
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Table 2 Individual level barriers to LA ART implementation and proposed solutions
Themes Provider Responses






“Attending 6-12 times/year instead of 2-3 and costs/
inconvenience associated with this.” (Australian provider)
Flexible scheduling, less frequent dosing
“Longer opening hours, patient auto-injection, take it every 8
weeks.” (Swedish provider)
“Having a 2 monthly injection would be better for patients to
work into their timeline/lifestyle/work schedule” (Australian
provider)
“The patient needs to come more often compared to oral
ART” (Swedish provider)
“Having to come for injection during regular opening hours
(from 8h00 to 16h00 for example).” (Canadian provider)
Increased access through multiple locations
“Develop pharmacies with injectable ARV management
capacity, similar to vaccinations.” (Argentinian provider)
“Health centers close to patients' homes for medication
administration.” (Spanish provider)
“Having to comply with injection window” (Argentinian
provider)
“The need to meet fixed administration deadlines” (Spanish
provider)
Patient education, support and guidance
“Appropriate patient education on the treatment to ensure
commitment to scheduled visits.” (French provider)
“Getting patients with unstable lifestyles to come to clinic”
(U.S. provider)
“Recall [smart phone] application for injection date.” (French
provider)
“Concerns over resistance in lost to follow up patients” (U.S.
provider)
“Making sure clear communication with patient on what is
required for medication.” (U.S. provider)
Information on bridging between LA and oral ART
“Know better how to go from the oral route to the I.M. and
vice versa in periods of different duration to better adapt ART
to the needs of patients” (Spanish provider)
“Flexibility to bridge with oral therapy when unable to come
in for injection.” (U.S. provider)
Tolerability of
injections
“Injection site pain, mostly related to RPV LA.” (Canadian
provider)
Train clinic staff on how to minimize reactions
“Reporting in detail local side effects of development studies
and facilitating administration guidelines to prevent them (if
known).” (Spanish provider)
“Possible local sequelae of the accumulation of IM injections
for life.” (Argentinian provider)
Advise patients on how to manage injection site reactions
“Appropriate injection technique and patient education for
pain management.” (U.S. provider)
“Drug-drug interactions, injection-related side effects” (Italian
provider)
“Fear of long-term effects at the puncture sites” (German
provider)
Patient-provider communication and patient support
“Since I have had experience with patients afraid of the
injections and have helped them successfully deal with this, I
can share this with other patients who may want to go on
the injectables but are afraid of the shots.” (U.S. provider)
“Fear of injections” (Russian provider) “Talking the patient through the whole process and what to
expect”(Australian provider)





“Selecting appropriate patients” (Australian provider) Patient-provider communication and decision-making
“To ensure patient is very well informed & has been given
plenty of time to consider this change.” (Australian provider)
“High virus suppression rate for long-term candidates” (South
Korean provider)
“Communication with the patient” (Russian provider)
“Adequate selection of patient profile” (Spanish provider) “Patient choice” (Argentinian provider)
“Ensure proper choice of candidates” (Russian provider) “Patient counselling & careful selection of appropriate
patients.” (South African provider)
U.S. “ Determination of which patient populations to
prioritize, both in resource-rich and constrained settings,
based on patient characteristics, adherence level, inadequate
virologic suppression rates, cost constraints, and accurate cost
projections” (U.S. provider)
“Carefully discuss options and benefits and challenges to
determine suitability” (U.S. provider)
“Respect patient preferences.” (Canadian provider)
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Provider barriers and proposed solutions
The main challenge identified by providers was deter-
mining appropriate candidates for LA ART. Throughout
the IDIs, providers reported mixed perspectives regard-
ing whether “adherent” or “non-adherent” patients were
the more appropriate LA ART candidates. For example,
providers were concerned about patients who travel fre-
quently and who may in turn not always be able to at-
tend their injection appointments. This issue led them
to consider placing such patients back on an oral
regimen. Providers often expressed a tension between
recognizing that non-adherent patients could be ap-
propriate candidates, while balancing their under-
standing that patients under this treatment modality
need to adhere to clinic appointments in order to re-
ceive their injections. This tension is captured in the
following quote:
The patient who is very badly adherent, this is the
patient that I am afraid to use an injectable treat-
ment on because that patient scares me if he/she is
lost and appears three weeks later than he/she had
to...The patient that would be theoretically a very
good candidate [is] that patient who is a disaster in
adherence. Because the injection is only one day, but
if on that day he/she does not come and he/she dis-
appears... [Spain male physician, Sub-P.I., ATLAS/
ATLAS-2M trials]
Nevertheless, there seemed to be a middle ground
that could be found between these two seemingly
mutually exclusive categories of “adherent” and “non-
adherent” patients, from the perspective of providers
who commented that it was about finding those pa-
tients who may have trouble taking pills; yet, are still
able to come in for injection appointments on a set
schedule. As shown in Table 2, proposed solutions
among survey respondents focused on patient-
provider communication and decision-making around
appropriateness of LA ART including resources to as-
sist with such conversations.
Clinic level considerations: infrastructure and staffing
Clinic level barriers primarily related to the logistical
challenges of increased volume of patients receiving LA
ART injections. Providers’ key concerns were around
capacity to meet demand including the need for add-
itional staff and skilled individuals to administer the in-
jections, shifts in workflow as demand increases, and the
logistics of cold-chain storage. An interview participant
in the U.S. described her concerns around how to man-
age logistics of providing LA ART to a large portion of
the patient caseload at her site:
We have 1200 people come to my clinic here, just for
example, and if most of them had to come every
month or even every other month and get an injec-
tion, I don’t know how we would physically be able
to do that with the infrastructure that we have. Just
space, the nurses, everything else. So just how to ac-
tually administer it. I think it’d be difficult to do in
the context of a busy outpatient clinic. (U.S. phys-
ician and PI, IDI participant)
Providers raised concerns around the time and ef-
fort that staff would need to dedicate to retention.
An interview participant in the U.S. described the
time and effort of one of her team members to get
trial participants back to the clinic for their injection
appointments:
She really has to do a lot of retention work with
keeping them coming to appointments; they don't
show and you have to call them to keep coming
back, they need that support. (U.S. nurse and study
coordinator, IDI participant)
Describing the need for adequate refrigeration and
storage facilities for cold chain logistics, one U.S.
interview participant said:
I want to be able to have it stocked in my re-
frigerator where I keep my vaccines but in a way
Table 2 Individual level barriers to LA ART implementation and proposed solutions (Continued)
Themes Provider Responses
Perceived Barriers Salient Proposed Solutions with
Representative Quotes
“Clinicians will likely be hesitant because of their concerns
regarding the potential to do harm, which may make them
less likely to want to offer the drug to their patients. Need to
take the practitioner comfort level out of the equation.”
(Canadian provider)
Resources to support provider-patient communication and
decision-making
“Patient-doctor guide” (French provider)
“Provider resources for coming off LA” (U.S. provider)
“Well screener observant and available patients before
proposing the injections and propose a provisional schedule
of injections established in advance” (French provider)
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in which there's a long shelf life, I don't have to
mess with it a lot. It has to come all preformed.
Long shelf life and preformed. (U.S. physician and
PI, IDI participant)
A solution proposed by numerous survey respondents
was to have a team of individuals to coordinate an injec-
tion program (e.g. designated staff for scheduling, injec-
tions, retention) with a dedicated clinic or injection rooms
on site for administering LA ART. A few interview partici-
pants suggested utilizing nursing staff already administer-
ing intramuscular injections (e.g. for sexually transmitted
infections (STIs)).
Many survey respondents across regions proposed
offering injections in other settings such as pharma-
cies to address the potential for a surge in demand
beyond what their clinic staff could handle. Several
interview participants in the U.S. and Spain discussed
the need to have LA ART administered in an array of
clinical care settings such as community health cen-
ters, family practices, or dedicated HIV treatment
centers. An interview participant in Spain described
how the expansion of services to other clinical set-
tings would aid with a potentially high influx of pa-
tients switching to LA ART:
If, in the future, a very high number of patients go
on to receive this treatment, surely it will have to be
taken from the hospital and brought to the health
centers because it will not be possible for us to have
900 patients coming here to get an injection. The
nurse would not be sufficient…. [Spain physician and
PI, IDI participant]
One U.S. interview participant who was very cognizant
that reaching non-adherent patients was important, des-
pite its difficulty, noted the potential similarities used for
injectable antipsychotic medications that follow a home-
based delivery model. This provider explained:
So if you use the analogy from long-acting antipsy-
chotics where these have been very successful, a lot of
the models work well when they have a visiting nurse
who will actually go to patients’ homes and give them
the medicine and keep tabs on them and really help
them with support in other areas, and those are the
models that work well, and so we need to develop
something like that for the patients that really can’t or
won’t take medicine every day. [U.S. physician and
PI, IDI participant]
As seen in Table 3, other solutions proposed by
survey respondents included staff training on work-
flow, logistics, injection procedures, and proper
temperature conditions for LA ART. Additional solu-
tions included providing incentives for staff involved
in the administration of injections and establishing
appropriate workflows and protocols.
Health system level considerations: cost and regulatory
approvals
Health system level barriers included issues around cost
and the need for approvals from regulatory bodies. Sur-
vey respondents across all regions expressed concern
around the cost of the drug, what portion of cost insur-
ance would cover, and how reimbursement would work
(Table 4). Respondents also focused on obtaining ap-
provals from the appropriate authorities within their
countries for dispensing the medication from hospital
pharmacies and having LA ART added to nationally cov-
ered medications lists.
Cost came up repeatedly throughout IDIs in Spain and
the U.S. as well. While among U.S. interview partici-
pants, most providers appeared to assume that insurance
companies would defray much of the costs associated
with LA ART, the issue of co-pays was raised in both
countries as a potential barrier, especially if LA ART was
significantly more expensive than daily oral ART.
Among Spain interview participants, given their univer-
sal government-run health care system, providers were
unsure whether the government would support a wide-
scale roll-out of LA ART. One Spain interview partici-
pant elaborated explaining that what “worries [him] is
that the cost is too high and the number of patients that
can be included would be relatively low.” (Spain, phys-
ician and PI, IDI participant). A U.S. interview partici-
pant described her concerns as follows:
I have a great concern about that from the reim-
bursement perspective, because..there are certain
things that I give here-- I actually take a loss on
that, so to me that's another big area of worry, be-
cause I have to be practical about that…It has to…
guarantee that I will not lose money. I don't need to
make money giving it, but I cannot lose money giving
it. (U.S. physician and PI, IDI participant)
Proposed solutions from survey participants fo-
cused on affordable drug pricing, governments sub-
sidizing treatment, co-pay assistance, a competitive
market that could lead to reduction in drug prices,
clear compensation guidelines, patient and clinic fi-
nancial support and ensuring cost coordination be-
tween pharmaceutical companies and insurance
carriers prior to roll-out. There were several country
specific responses. For example, in the U.S., respon-
dents proposed expanding Medicare to include LA
ART and having adequate approvals with the AIDS
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Drug Assistance Program (ADAP) and commercial
insurances while respondents from Mexico men-
tioned ensuring that LA ART enters the basic drug
treatment list (“cuadro básico” in Spanish) allowed
in the country.
Several of the previously mentioned solutions were
proposed by providers when thinking about how to
address cost barriers they anticipated their site would
experience with LA ART. These included self-
administration, alternative facilities for administration,
and offering less frequent dosing. Proposed solutions
for the barrier of getting approvals from regulatory
bodies focused on simplifying the registration process
for new drugs.
Table 3 Clinic level implementation barriers to LA ART and proposed solutions
Themes Provider Responses





“Keeping track of timing/scheduling of patient appointments,
window for injections & follow up with patients that miss
injections.” (U.S. provider)
Train clinic staff
“Logistics collaboration, training of health personnel, access and
infrastructure” (Argentinian provider)
“Infrastructure in the centers for its application and conservation
of the drug.” (Argentinian provider)
Designate staff/space for injections
“Dedicated clinic or team” (Italian provider)
“Injection rooms and specialists dedicated to the provision of
injections, providing incentives to the staff involved in the
administration of injections” (South Korean provider)
“We would need to organize a team to look at assigning
personnel to be in charge of supply, education, administration,
and patient retention.” (U.S. provider)
“Staff coordination for delivery of injections.” (South Korean
provider)
“Need of personnel and physical space for its administration”
(Spanish provider)
“Clinic time demands for injections” (U.S. provider) Establish workflows and protocols
“Suggested workflow example of a typical patient injection visit”
(Australian provider)
“Work the injection appointments into clinic flow/create template
for scheduling injection visits; staff training (drug ordering and
storage, administration of injections, follow up/window allowed
for injections); pharmacy tech trained on prior authorizations/
insurance” (U.S. provider)




“The need for a strict cold chain.” (Russian provider) Train clinic staff
“Training in clinics to educate staff about temperature needed to
keep medications at and importance of proper dosing and
temperature of medications.” (U.S. provider)
“Cold chain in rural areas” (South African provider)
“Cold chain issues. Drug only free at one pharmacy in Melbourne
and cold chain would therefore be broken.” (Australian provider)
Adequate refrigeration and storage facilities
“Would potentially need medication sent by a courier if patients
don't wish to pay for it to ensure cold chain maintained.”
(Australian provider)
Table 4 System level implementation barriers to LA ART and proposed solutions
Themes Provider responses
Perceived barriers Salient proposed solutions with representative quotes
Cost - equivalency
to oral ART
“Possible high costs.” (Argentinian provider)
“Cost constraints, and accurate cost projections.” (U.S.
provider)
“Cost of drug to physicians for purchasing for the
office” (U.S. provider)
Competitive cost with oral ART
“Pricing must be equivalent to standard therapy.” (German provider)
“Provision of LA regimen free to the public sector” (South African
provider)





“Reimbursement for the medication.” (German provider)
“Potentially the overall cost for insurance carriers (i.e.
doctor visits + injections + medication cost).” (U.S.
provider)
“Insurance issues, insurance reimbursement for clinic
injection visits.” (U.S. provider)
Government-subsidized treatment
“Having adequate approvals with ADAP, Medicare, and commercial
insurances.” (U.S. provider)
Co-pay assistance
“Copay cards or assistance for patients with and without insurance”
(U.S. provider)
Clear compensation guidelines for clinics
“Clear guidelines regarding compensation for the increased number
of visits that injection treatment generates, we would end up with
our order and not receive reimbursement for our costs - in short, the
economy controls and in this case the staff cost.” (Swedish provider)
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Multi-level model for optimal implementation of LA ART
To consolidate and organize our findings, we developed
a multi-level model (Fig. 1) depicting the key consider-
ations identified in this study to inform how providers,
clinics and health systems may begin to consider and ad-
dress potential challenges they may encounter when
introducing LA ART into their clinical settings. We
drew on the CFIR to inform the development of this
model situating findings within the established and well-
understood domains of the individual, inner setting, and
outer setting [40]. At the center of the model is LA ART
with its core components. Around it lie the individual
and clinic levels with their borders curved to encircle LA
ART illustrating the need for changes or adaptations to
elements and processes at those levels to facilitate LA
ART implementation.
Shown in rectangles surrounding the intervention
are the potential barriers to implementation identified
at each level by providers in this study. Their pro-
posed solutions to address these barriers are shown
in arrows pointing towards the intervention. Within
the individual and clinic level, the key component
critical to implementation as indicated by study find-
ings is shown at top. These key components are
patient-provider communication and decision-making
at the individual level and workflow and logistics pro-
tocols addressing staffing and infrastructure challenges
at the clinic level. Potential barriers and proposed so-
lutions at the systems level are shown along the bot-
tom of the figure separated from all factors in the
inner setting indicating that they will be addressed by
external entities separately from the more proximal
implementation strategies that can be addressed
through implementation plans.
Discussion
Study findings reveal individual, clinic, and health system
level considerations for administering LA ART as part of
routine clinical care. This lays the groundwork for the
development of needs assessments and implementation
research across diverse types of clinical care facilities
and geographic settings outside of an efficacy trial. Im-
plementation science must play a key role in guiding the
process of moving LA ART from clinical trials to real-
world settings [41, 42]. Future studies can tailor imple-
mentation strategies to address some of the perceived
barriers and proposed solutions identified in this study
to optimize implementation effectiveness and success.
Findings underscore the need for a multi-level strategy
to bring LA ART from trials to the field and have several
implications for research and practice. At the system
level, issues around cost and regulatory approvals rely
on external bodies and will vary for each site depending
on their national health system. Nonetheless, providers
and clinic leadership will have to navigate how their sites
are going to interact with and operate within established
systems and mechanisms. At the individual and clinic
level however, findings suggest several factors that
should be considered in future implementation research
and planning. Our model of Multi-level Considerations
for Implementing LA ART (Fig. 1) highlights opportun-
ities to make adaptations to elements and processes
within the inner setting [40] at both the individual and
clinic level which could address potential barriers
Fig. 1 Multi-level Considerations for Implementing LA ART
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identified in this study. For example, focusing on accom-
modating patient needs and preferences and providing
supportive services and resources for patients may be
important to implementation success, as may facilitating
effective communication and shared decision-making
between patients and providers regarding the appropri-
ateness of an LA ART regimen. This work builds on our
prior research documenting patient perspectives on LA
ART [25–27] by adding provider prespectives on
patient-centered approaches to improving uptake and
adherence of this treatment modality. At the clinic level,
assessing clinic readiness is paramount. The barriers and
solutions identified in this study can be used to help
guide clinic assessments of what resources will be
needed to support the introduction of LA ART and to
determine what is feasible at sites given their specific
setting and circumstances.
Using the factors in our model of Multi-level Consid-
erations for Implementing LA ART (Fig. 1), clinical sites
can distill specific strategic implementation guidance on
how to support patients and providers at the individual
level and how to strengthen staffing and infrastructure
at the clinic level. For example, at the individual level,
patients and providers may benefit from using shared
decision-making tools that guide their dialogues to help
them reach a decision on whether LA ART is an appro-
priate fit. Providers may benefit from materials on and
platforms for navigating clinical considerations of LA
ART such as bridging with oral therapy, lead-in periods
and pharmacokinetic tails. At the clinic level, checklists
for refrigeration requirements and suggestions for effect-
ive and space-saving storage strategies would provide
concrete support on logistical aspects. Training manuals
including examples of typical patient injection visits and
sample team work designation structures could help
address workflow and staffing questions. Our model
(Fig. 1) is also intended to offer insights and highlight
priority areas for future implementation research. Fu-
ture studies can further identify key strategic next
steps by examining the factors highlighted here to in-
form effective implementation of LA ART in real-
world contexts.
Based on the guidance providers expressed they would
need to scale up LA ART, potential resources to support
clinical sites in navigating this new treatment modality
could include: training manuals on administering injec-
tions, medication management protocols, guidance to fa-
cilitate patient-provider communication and decision-
making around appropriate candidates for LA ART.
However, research on the sources of information that
clinicians use has found that colleagues often rank as
primary information sources and that informal learning
is widespread [43–46], suggesting the importance of in-
ternal champions at individual sites. Individuals who can
actively promote the LA ART implementation process
[40] and facilitate knowledge sharing among staff and
clinicians could potentially help sites adopt this new
treatment modality.
As indicated by several survey participants (Table 2)
(e.g. “offer a support platform for patients”, “recall
[smart phone] application for injection date”, “online
peer navigators”), the use of technology and online re-
sources should be explored as an opportunity to provide
what was perceived as much needed patient support for
LA ART delivery. Evidence of such strategies has shown
to be successful in encouraging appointment adherence
[47, 48], fostering virtual health communities among
chronic-disease patients [49], and providing support net-
works for stigmatized populations [50]. With the poten-
tial to address some of the key barriers providers
perceived to patient success on LA ART, these strategies
warrant further consideration and research.
Reflecting on the findings from this study, there are sev-
eral broader implications to consider. Providers’ concerns
about cost raise important questions around appropriate
candidates given that, from a health system perspective, it
may be necessary to potentially prioritize LA ART for those
with the greatest unmet need. Thus, research on appropri-
ate candidates for this treatment modality [51] is critical to
help determine which patient populations to prioritize, both
in resource-rich and constrained settings. Given re-
cent results from HIV Prevention Trials Network
(HPTN) 083 demonstrating that long-acting injectable
CAB as LA pre-exposure prophylaxis (PrEP) is highly
effective [52], findings from this study may also high-
light important considerations for delivery of LA PrEP
outside of clinical trials. Finally, given the current cli-
mate in which COVID-19 has significantly impacted
many health systems around the world, launching a
novel treatment such as LA ART brings additional
challenges. In addition to the current pandemic ex-
acerbating challenges identified in this study as clinic
personnel are stretched and tasks are multiplied, indi-
viduals’ healthcare priorities are shifting as they assess
personal risk and safety in accessing care at clinics.
These considerations should be taken into account
for thoughtful roll-out of this treatment modality in
the current context.
This study had several limitations. First, the possibility
for bias exists in both samples of data used in this analysis
as all providers were participating in a clinical trial and
thus their views and experiences may reflect a potential
openness and predisposition to the acceptability and use
of LA ART. Second, the sample is not representative as
participants were disproportionately from the West (U.S.
and Europe) and certain regions were represented by only
one or two countries. Given that the perspectives of low-
and middle-income countries (LMICs) were
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underrepresented in this study, considerations for effective
LA ART in these settings will need to be further explored
and cognizant of local contexts, since health system chal-
lenges and opportunities may be different. Additionally,
sites participating in clinical trials are likely more prepared
with the needed resources to begin LA ART implementa-
tion than more rural sites or even urban sites in resource-
constrained settings. Finally, the current study is formative
research not conducted in a real-world sample; rigorous
implementation research should be carried out to examine
direct translation to routine care. In an effort to avoid
common pitfalls of semi-structured interviews including
the possibility of bias introduced by the interviewer, we re-
lied on experienced qualitative researchers trained in
using a flexible guide and with working knowledge of the
topic so as to establish trust, rapport, and active listening
on the part of the interviewer with the participant. The re-
searchers utilized memo writing to document thoughts,
comparisons, and questions, and to reflect on interviewer
perceptions to manage biases, assumption, and reactions
to the data. This study had several strengths including that
findings were validated through triangulation as we uti-
lized data from different sources collected from partici-
pants in different regions of the world. Additionally, we
found high levels of convergence across the two data
sources on the key domains reported here.
Conclusion
Study findings highlight the importance of a multi-level
strategy to bring LA ART from clincal trials to routine care.
Results suggest the importance of multi-tiered support sys-
tems to optimize patient-provider communication and
treatment decision-making; clinic staffing, workflow, logis-
tics protocols and infrastructure; as well as access and cost-
related factors within a given health system. Key consider-
ations identified in this study can inform future implemen-
tation research and plans for scale-up.
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